Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

DC-ren

Financiado

Cerrado

Drug combinations for rewriting trajectories of renal pathologies in type II dia...

Drug combinations for rewriting trajectories of renal pathologies in type II diabetes DC ren Diabetic Kidney Disease (DKD) is highly prevalent in type 2 diabetes, with major impact on patients and healthcare systems. The complex disorder, further modulated by cardiovascular comorbidities, presents as an accumulation of ri... ver más

31/12/2024

MUI

6M€

Presupuesto del proyecto: 6M€

Líder del proyecto

MEDIZINISCHE UNIVERSITAT INNSBRUCK No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 8 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2024-12-31

SC1-BHC-02-2019: Systems approaches for the discover...

I+D

Cerrada hace 6 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

8 Participantes

MUI

1.23M€ | Lider

WEIZMANN

515.24K€ | Participante

UNIVERSITAIR MEDISCH CENTRUM...

554.93K€ | Participante

UNIVE

781.41K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PROMINENT Personalised Medicine in Diabetic Chronic Disease Management 3M€ Cerrado

BEAt-DKD Biomarker Enterprise to Attack DKD Sofia ref. 115974 31M€ Cerrado

PICKED PersonalIzed medicine in Chronic KidnEy Disease Cerrado

PRIME-CKD Personalized Drug Response: IMplementation and Evaluation in... 9M€ Cerrado

SYSKID Systems biology towards novel chronic kidney disease diagnos... 16M€ Cerrado

DECODE-DKD Decoding diabetic kidney disease 2M€ Cerrado

Duración del proyecto: 60 meses Fecha Inicio: 2019-12-13
Fecha Fin: 2024-12-31

Líder del proyecto

MEDIZINISCHE UNIVERSITAT INNSBRUCK No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 6M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Diabetic Kidney Disease (DKD) is highly prevalent in type 2 diabetes, with major impact on patients and healthcare systems. The complex disorder, further modulated by cardiovascular comorbidities, presents as an accumulation of risk factors, which we treat with drug combinations. While the overall benefit of this approach is evident on a cohort level, individual patients show remarkable heterogeneity in drug response, and lack of guidance on personalized medication results in suboptimal control of the disorder. For resolving variability, we propose a new concept for personalization of drug combinations beyond the cohort-centric perspective. We improve patient stratification based on equivalence relations of clinical presentation, disease pathophysiology and drug combinations. The approach is derived from dynamical systems theory, aimed at reducing probabilistic assignment of patient-specific disease evolution and matching drug combinations. The availability of a large European repository holding DKD patients in routine care with diverse drug combinations, complemented by high-throughput screening for improving patient phenotyping, and molecular network modelling of pathology, embedded risk factor combinations and consequence of drug effect allows a systems representation of patient groups. Integrating clinical presentation and molecular architecture in a novel computational framework will establish a decision support software prototype. We will validate this tool for predicting optimized personalized drug combinations in a study using given clinical trial repositories. Demonstration will expand to other available drugs, which in combination with approved drugs promise benefit for groups of DKD patients. With a clear route toward uptake in the clinical setting, and generalization capacity of our approach to other complex disorders we foster next steps in personalization, anticipate major patient benefit, and see novel translation and business opportunities.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores